Raloxifene Hydrochloridum CAS:82640-04-8

Raloxifenum hydrochloridum, secunda-generatio Selectiva Estrogen Receptor Modulator (SERM) in Raloxifene hydrochloride benzothiophene familia. Idus Septembris 13, 2007, U *. S. Cibum et medicamentum Administrationis Evista approbavit de reductione in periculo canceris pectoris incursionis in mulieribus postmenopausalibus cum et in hydrochloride Raloxifene sine osteoporosis.. Etiam probatus est ut sola osteoporosis curatio potentis sto- ricana.

Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women have undergone menopause. Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue).

Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.